Brokerages Anticipate Mustang Bio Inc (MBIO) Will Announce Earnings of -$0.20 Per Share
Wall Street brokerages expect that Mustang Bio Inc (NASDAQ:MBIO) will post ($0.20) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Mustang Bio’s earnings. Mustang Bio posted earnings of ($0.27) per share during the same quarter last year, which indicates a positive year over year growth rate of 25.9%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Mustang Bio will report full-year earnings of ($0.84) per share for the current fiscal year. For the next financial year, analysts expect that the firm will post earnings of ($0.90) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Mustang Bio.
Mustang Bio (NASDAQ:MBIO) last released its earnings results on Monday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06.
MBIO traded up $0.15 on Wednesday, hitting $6.33. 1,311 shares of the company were exchanged, compared to its average volume of 90,719. Mustang Bio has a 12 month low of $5.87 and a 12 month high of $13.35. The firm has a market capitalization of $173.79 million and a PE ratio of -8.24.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MBIO. Wells Fargo & Company MN acquired a new position in Mustang Bio during the fourth quarter worth approximately $164,000. Geode Capital Management LLC acquired a new position in Mustang Bio during the fourth quarter worth approximately $639,000. Goldman Sachs Group Inc. acquired a new position in Mustang Bio during the fourth quarter worth approximately $131,000. Millennium Management LLC acquired a new position in Mustang Bio during the fourth quarter worth approximately $326,000. Finally, Northern Trust Corp increased its position in Mustang Bio by 76.7% during the first quarter. Northern Trust Corp now owns 28,364 shares of the company’s stock worth $310,000 after buying an additional 12,316 shares during the last quarter. Institutional investors and hedge funds own 4.78% of the company’s stock.
Mustang Bio Company Profile
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.
Recommended Story: Average Daily Trade Volume – ADTV
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.